Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter seriesPeter A. Nigrović, Gloria C. Higgins, Melissa L. Mannion et al.|Arthritis & Rheumatism|2010Cited by 465
Factors Associated With Treatment Response to Etanercept in Juvenile Idiopathic ArthritisM.H. Otten, Lisette W. A. van Suijlekom‐Smit, Esther P A H Hoppenreijs et al.|JAMA|2011Cited by 149
MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritisJanneke Anink, Dirk Holzinger, Lisette W. A. van Suijlekom‐Smit et al.|Arthritis Research & Therapy|2015Cited by 81
Tumor Necrosis Factor-blocking Agents for Children with Enthesitis-related Arthritis — Data from the Dutch Arthritis and Biologicals in Children Register, 1999–2010M.H. Otten, Lisette W. A. van Suijlekom‐Smit, Femke H. M. Prince et al.|The Journal of Rheumatology|2011Cited by 73
Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC RegisterM.H. Otten, Lisette W. A. van Suijlekom‐Smit, Femke H. M. Prince et al.|Annals of the Rheumatic Diseases|2012Cited by 59